Sandoz’s Biosimilar Pegfilgrastim Receives CHMP Approval for Febrile Neutropenia

 Sandoz’s Biosimilar Pegfilgrastim Receives CHMP Approval for Febrile Neutropenia

Sandoz’s Erelzi (etanercept, biosimilar) Receives Health Canada Approval for Psoriatic Arthritis (PsA) in Adults

Shots:

  • The CHMP approval is based on data demonstrating analytical, preclinical, and clinical information, confirming biosimilar pegfilgrastim as a reference medicine in febrile neutropenia in terms of safety, efficacy and quality
  • The biosimilar pegfilgrastim will be available in the 28 countries of EU post European Commission approval, which usually adopts CHMP positive opinion
  • Pegfilgrastim is a long-acting form of filgrastim that stimulates the production of WBCs and stem cells and Sandoz, is seeking its approval as a reference medicine for Febrile Neutropenia in EU

Click here to read full press release/ article | Ref: Sandoz | Image: Elglobal

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post